PETALING JAYA: Genting Bhd shares surged 10% to RM5.24 after its 20.3% subsidiary TauRx Pharmaceuticals Ltd revealed initial data from an Alzeimer’s drug clinical trials.

       “TauRx’s lead investigative oral drug, hydromethylthionine mesylate, was tested on 598 people with Alzheimer’s.

       “Following the 12-month blinded phase of the study, TauRx announced that the participants of the study have moved to an additional one-year open label phase,” said Genting in a statement yesterday.